Original synthesis to sit alongside the encyclopedia article below. Not part of Wikipedia; verify facts on Wikipedia when precision matters.
Minocycline (Chinese common name: 二甲胺四环素) is a semi-synthetic broad-spectrum antibiotic belonging to the tetracycline class. It exerts bacteriostatic effects by targeting the 30S subunit of bacterial ribosomes to block protein synthesis, and is widely used to treat a range of bacterial infections and chronic dermatological conditions.
Key moments
1961First formal regulatory approval for clinical use as an anti-infective agent
1971Received full marketing approval from the US FDA for general clinical practice
2000sLow-cost generic formulations became widely available globally, with over 4 million annual prescriptions issued annually in the US alone
Unique pharmacological advantages among tetracyclines
Minocycline stands out from older tetracycline drugs for its extremely high lipophilicity, nearly 100% oral absorption that is barely affected by food consumption, and far superior tissue penetration. It can reach therapeutically effective concentrations in the central nervous system, prostate tissue and saliva that most other tetracycline agents cannot easily achieve, and it has the strongest documented antibacterial activity against resistant gram-positive pathogens among all approved tetracycline medications.
Expanded non-antibacterial research and off-label uses
Beyond its standard approved infection treatment indications, researchers have been investigating the separate anti-inflammatory and neuroprotective properties of minocycline for years. There are ongoing clinical trials evaluating its potential utility for a wide range of non-infectious conditions including multiple sclerosis, rheumatoid arthritis, acute kidney injury, and some neurodegenerative diseases, though none of these expanded uses have received full formal regulatory approval as of 2026.
Evolving safety guidance for long-term use
While short courses of minocycline are generally well tolerated, long-term continuous prescriptions for chronic acne management have been linked to rare but severe adverse events including drug-induced autoimmune hepatitis, pigmentation disorders that can cause permanent skin discoloration, and hypersensitivity syndromes. Modern clinical guidelines now recommend limiting unbroken long-term minocycline courses where possible, and preferring lower-dose extended-release formulations to minimize cumulative side effect risks.
Minocycline, sold under the brand name Minocin among others, is a tetracycline antibiotic medication used to treat a number of bacterial infections such as some occurring in certain forms of pneumonia.[2] It is generally (but not always) less preferred than the tetracycline doxycycline.Minocycline is also used for the treatment of acne and rheumatoid arthritis.[5] It is taken by mouth or applied to the skin.[6][7]
Common side effects include nausea, diarrhea, dizziness, allergic reactions, and kidney problems.[6] Serious side effects may include anaphylaxis, a lupus-like syndrome, and easy sunburning.[6] Use in the later part of pregnancy may harm the baby and safety during breastfeeding is unclear.[8] It works by decreasing a bacterium's ability to make protein thus stopping its growth.[6]
Minocycline was patented in 1961 and came into commercial use in 1971.[9] It is available as a generic medication.[5][10] In 2022, it was the 269th most commonly prescribed medication in the United States, with more than 900,000 prescriptions.[11][12]
Medical uses
Acne
Minocycline and doxycycline are frequently used for the treatment of acne vulgaris.[13][14] Minocycline is specifically indicated to treat inflammatory lesions of non-nodular moderate to severe acne vulgaris in people nine years of age and older.[15][7] Both minocycline and doxycycline have similar levels of effectiveness and common adverse effects for acne, although doxycycline may have a slightly lower risk of adverse side effects.[15][16]
Contraindications
The drug is contraindicated in people with known hypersensitivity to tetracycline antibiotics, as there is complete cross sensitivity in this group.It is also contraindicated in people with severe liver impairment and after the 16th week of pregnancy.[3]
Side effects
Minocycline may cause upset stomach, diarrhea, dizziness, unsteadiness, drowsiness, mouth sores, migraines, and vomiting.It increases sensitivity to sunlight, and may affect the quality of sleep and rarely causes sleep disorders.[38] It has also been linked to cases of lupus.[39] Prolonged use of minocycline can lead to blue-gray staining of skin, fingernails, and scar tissue.This staining is not permanent, but can take a very long time for the skin color to return to normal; however, a muddy brown skin color in sun-exposed areas is usually permanent.[40] Permanent blue discoloration of gums or teeth discoloration may also occur.Rare but serious side effects include fever, yellowing of the eyes or skin, stomach pain, sore throat, vision changes, and mental changes, including depersonalization.[41][42]
Overdose
Symptoms of minocycline overdose may include dizziness, nausea, and vomiting.[2] There is no specific antidote for overdose of minocycline and treatment should be symptom-based and supportive.[2] The drug is not removed by hemodialysis or peritoneal dialysis.[2]
Interactions
The combination of minocycline with dairy, antacids, calcium and magnesium supplements, iron products, laxatives containing magnesium, or bile acid sequestrants may decrease minocycline's effectiveness by forming chelates.Combining it with isotretinoin, acitretin or other retinoids can increase the risk for intracranial hypertension.Minocycline significantly reduces concentrations of the anti-HIV drug atazanavir in the body.[3][63]
Pharmacology
Pharmacodynamics
Antibiotic activity
Minocycline mediates its antibiotic activity by binding to the 30S ribosomal subunit of bacteria and thereby inhibiting protein synthesis.[64][65] It is primarily bacteriostatic.[2] The drug is a broad-spectrum antibiotic and shows activity against a wide range of both Gram-positive and Gram-negative bacteria.[64][65]
Chemistry
Minocycline is a tetracyclinederivative.[74] It is closely structurally related to other tetracyclic antibiotics such as tetracycline, doxycycline, and tigecycline.[74]
The drug is used in form of minocycline hydrochloridedihydrate,[71] which is sparingly soluble in water and slightly soluble in ethanol.Minocycline reacts acidic in aqueous solution.[3]
The partition coefficient (P) of minocycline has been reported to be 39.4 (i.e., log P of 1.60).[75]
History
Minocycline was patented in 1961, was first described in the scientific literature in 1967,[79] and came into commercial use in 1971.[9] A topicalfoam for treatment of acne was approved in 2019.[7]
Society and culture
Brand names
Minomycin
Minostad (in Europe, for the treatment of acne)
Akamin
Minocin
Minoderm
Cyclimycin
Arestin (1-mg doses administered locally into periodontal pockets, after scaling and root planing, for treatment of periodontal disease.)[80]
Nomika (in Indonesia)
Aknemin
Solodyn (extended-release, for the treatment of acne)
Dynacin
Sebomin
Research
Neuropsychiatric disorders
Depression
Minocycline has been studied in the treatment of depression.According to a 2023 systematic review of minocycline for treatment-resistant depression based on four clinical trials, "There is no significant difference with minocycline compared to placebo for depression not responding to first-line antidepressant therapy."[81] Likewise, a 2025 systematic review and meta-analysis of four randomized controlled trials found that minocycline was not significantly more effective than placebo in treating depression.[82] Minocycline might have some benefit in treatment-resistant depression with inflammation however.[83] Yet another meta-analysis, also published in 2023, found that minocycline was effective in the treatment of depression, including treatment-resistant depression, with a small to moderate
Historically, oral minocycline has been an effective treatment for acne vulgaris.[18] However, acne that is caused by antibiotic-resistant bacteria is a growing problem in many countries.[19] In Europe and North America, a number of people with acne no longer respond well to treatment with tetracycline family antibiotics because their acne symptoms are caused by bacteria (primarily Cutibacterium acnes) that are resistant to these antibiotics.In order to reduce resistance rates as well as increase the effectiveness of treatment, oral antibiotics should be generally combined with topical acne creams such as benzoyl peroxide or a retinoid (tretinoin, adapalene, etc.).[20] There have also been concerns about systemic minocycline having a variety of rare adverse effects in terms of its use to treat acne.[15]
Oral minocycline is used to treat acne for up to 3 to 4months.[15] Data beyond 3 to 4months are limited.[15]
Other infections
Minocycline is also used for other skin infections such as methicillin-resistant Staphylococcus aureus.[21]
Although minocycline's broader spectrum of activity, compared with other members of the group, includes activity against Neisseria meningitidis,[22] its use for prophylaxis is no longer recommended because of side effects (dizziness and vertigo).
It may be used to treat certain strains of methicillin-resistant S. aureus infection and a disease caused by drug-resistant Acinetobacter spp.[23]
A list of uses includes:
Minocycline has been reported to be effective in the eradication of UTIs and prostatitis.[28][29] A 2013 Cochrane review identified and included two comparative clinical trials of minocycline for chronic bacterial prostatitis.[28] For this condition, minocycline has been found to be equivalent or superior to doxycycline,[30][31] equivalent to trimethoprim/sulfamethoxazole,[32][33] and superior to the first-generation cephalosporincephalexin.[34][28][35] It was also equivalent to the fluoroquinoloneofloxacin in the treatment of chronic bacterial prostatitis caused by Ureaplasma urealyticum.[28][36] Treatment durations of minocycline for chronic bacterial prostatitis have ranged from 2 to 4weeks.[28][31][33][35][36]
Amoebic dysentery
Anthrax
Bubonic plague
Cholera
Ehrlichiosis
Gonorrhea (when penicillin cannot be given)
Gougerot-Carteaud syndrome (confluent and reticulated papillomatosis)
Minocycline is available in the form of 50 and 100mg oralcapsules, among a variety of other formulations.[2][37] The oral form of minocycline is usually taken twice daily, once every 12hours, although divided doses four times daily can also be employed.[2]Extended-release oral forms are also available.[37] A topical formulation is available as well.[15][17][37]
Occasionally, minocycline therapy may result in autoimmune disorders such as drug-related lupus and autoimmune hepatitis, which usually occurs in men who also developed minocycline-induced lupus; however, women are more likely to develop minocycline-induced lupus. Significant or complete recovery occurs in most people who develop minocycline-induced autoimmune problems within a period of a few weeks to a year of cessation of minocycline therapy. Autoimmune problems emerge during chronic therapy, but can sometimes occur after only short courses of a couple of weeks of therapy.[43][44]Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome can occur during the first few weeks of therapy with minocycline.[44]
Minocycline, but not other tetracyclines, can cause vestibular disturbances, including symptoms of dizziness, ataxia, vertigo, and tinnitus.These effects are thought to be related to minocycline's greater penetration into the central nervous system. The vestibular side effects are much more common in women than in men, reportedly occurring in 50 to 70% of women receiving minocycline. However, other sources state that vestibular side effects occur in only 1 to 10% of patients. In any case, other studies have found that side effects occur more frequently in women than in men (~58% vs. 34%, respectively). Due to its vestibular side effects, minocycline has been said to be rarely used in female patients.[45] Minocycline's vestibular side effects typically resolve after discontinuation of the drug.[46][47][48][49]
Symptoms of an allergic reaction include rash, itching, swelling, severe dizziness, and trouble breathing.[41] Minocycline has also been reported to very rarely cause idiopathic intracranial hypertension (pseudotumor cerebri),[50] a side effect also more common in female patients, potentially leading to permanent vision damage if not recognized early and treated.[51]
Contrary to most other tetracycline antibiotics (doxycycline excluded), minocycline may be used in those with kidney disease, but may aggravate systemic lupus erythematosus.[52] It may also trigger or unmask autoimmune hepatitis.[53]
Minocycline can cause the rare condition of secondary intracranial hypertension, which has initial symptoms of headache, visual disturbances, dizziness, vomiting, and confusion.[54]Brain swelling and rheumatoid arthritis are rare side effects of minocycline in some people.[55]
Minocycline, like most tetracyclines, becomes dangerous past its expiration date.[56] While most prescription drugs lose potency after their expiration dates, tetracyclines are known to become toxic over time.Expired tetracyclines can cause serious damage to the kidney due to the formation of a degradation product, anhydro-4-epitetracycline.[56] Minocycline's absorption is impaired if taken at the same time of day as calcium or iron supplements.Unlike some of the other tetracycline group antibiotics, it can be taken with calcium-rich foods such as milk, although this does reduce the absorption slightly.[57]
Minocycline, like other tetracyclines, is associated with esophageal irritation and ulceration if insufficient fluids are taken with the drug before sleep.[58]
A 2007 study suggested that minocycline harms amyotrophic lateral sclerosis (ALS) patients. Patients on minocycline declined more rapidly than those on placebo. The mechanism of this side effect is unknown, although a hypothesis is that the drug exacerbated an autoimmune component of the primary disease. The effect does not seem to be dose-dependent because the patients on high doses did not do worse than those on the low doses.[59]
Other possible rare side effects of minocycline include hyperpigmentation and hypersensitivity reactions, among others.[15][60] It has been associated with more rare and serious adverse effects than other tetracyclines.[61] Some of the rare adverse effects of minocycline may result in death.[61][60] This has spurred interest in topical instead of systemic minocycline for treatment of acne.[61][15]
Minocycline is another drug known to cause leukopenia.[source? Known by whom?]
Minocycine has shown thyroid toxicity in animals, including in rodents, mini pigs, dogs, and monkeys.[2]
The use of minocycline to treat acne has been associated with skin and gut dysbiosis (see antibiotic misuse).[62]
Other activities
Minocycline shows a number of off-target activities in addition to its antibiotic activity.[66][65] These include inhibition of matrix metalloproteinases (MMPs), anti-inflammatory effects, antiapoptotic effects, antioxidant effects, and neuroprotective effects.[66][65]
Some other reported activities of minocycline include:
Suppression of the mouse's locomotor activity = 0.5mg/kg[69]
Indirect inhibition of inducible nitric oxide synthase[70]
Antibiotic activity
Minocycline mediates its antibiotic activity by binding to the 30S ribosomal subunit of bacteria and thereby inhibiting protein synthesis.[64][65] It is primarily bacteriostatic.[2] The drug is a broad-spectrum antibiotic and shows activity against a wide range of both Gram-positive and Gram-negative bacteria.[64][65]
Other activities
Minocycline shows a number of off-target activities in addition to its antibiotic activity.[66][65] These include inhibition of matrix metalloproteinases (MMPs), anti-inflammatory effects, antiapoptotic effects, antioxidant effects, and neuroprotective effects.[66][65]
Some other reported activities of minocycline include:
Suppression of the mouse's locomotor activity = 0.5mg/kg[69]
Indirect inhibition of inducible nitric oxide synthase[70]
Pharmacokinetics
Absorption
Minocycline is quickly and nearly completely absorbed from the upper part of the small intestine. Taking it together with food, including milk, has no relevant influence on resorption. It reaches highest blood plasma concentrations after 1 to 2hours.
Distribution
The drug has a plasma protein binding of 70 to 75%.It penetrates into almost all tissues; very high concentrations are found in the gallbladder and liver.It crosses the blood–brain barrier better than doxycycline and other tetracyclines, reaching therapeutically relevant concentrations in the cerebrospinal fluid and also in inflamed meninges.[3][71] Minocycline achieves good concentrations in the urinarybladder, and many other tissues.It shows excellent penetration into the prostate gland.[72] However, while permeation of prostate tissue and semen is good, levels are lower in prostatic fluid.
Metabolism
Minocycline is inactivated by metabolism in the liver to about 50%.It is primarily metabolized into 9-hydroxyminocycline.[73] Two N-demethylated metabolites are also formed.[73]
Elimination
The rest is predominantly excreted into the gut (in part via the gallbladder, in part directly from blood vessels) and eliminated via the feces. About 10–15% are eliminated via the kidneys. It is excreted about 5 to 10% unchanged in urine.[72] For comparison, other tetracyclines, like doxycycline and tetracycline, are excreted 30 to 70% unchanged in urine.[72] The biological half-life of minocycline is 11 to 26hours in healthy people,[6] up to 30hours in those with kidney failure,[6] and significantly longer in those with liver disease.[3][71]
Absorption
Minocycline is quickly and nearly completely absorbed from the upper part of the small intestine. Taking it together with food, including milk, has no relevant influence on resorption. It reaches highest blood plasma concentrations after 1 to 2hours.
Distribution
The drug has a plasma protein binding of 70 to 75%.It penetrates into almost all tissues; very high concentrations are found in the gallbladder and liver.It crosses the blood–brain barrier better than doxycycline and other tetracyclines, reaching therapeutically relevant concentrations in the cerebrospinal fluid and also in inflamed meninges.[3][71] Minocycline achieves good concentrations in the urinarybladder, and many other tissues.It shows excellent penetration into the prostate gland.[72] However, while permeation of prostate tissue and semen is good, levels are lower in prostatic fluid.
Metabolism
Minocycline is inactivated by metabolism in the liver to about 50%.It is primarily metabolized into 9-hydroxyminocycline.[73] Two N-demethylated metabolites are also formed.[73]
Elimination
The rest is predominantly excreted into the gut (in part via the gallbladder, in part directly from blood vessels) and eliminated via the feces. About 10–15% are eliminated via the kidneys. It is excreted about 5 to 10% unchanged in urine.[72] For comparison, other tetracyclines, like doxycycline and tetracycline, are excreted 30 to 70% unchanged in urine.[72] The biological half-life of minocycline is 11 to 26hours in healthy people,[6] up to 30hours in those with kidney failure,[6] and significantly longer in those with liver disease.[3][71]
However, other sources have stated the experimental log P of minocycline to be 0.05,
Early research has found a tentative benefit from minocycline in schizophrenia,[85] with several trials underway as of 2012.[86] A 2014 meta-analysis found minocycline may reduce negative and total symptom scores and was well tolerated.[87] A 2019 meta-analysis, which included 13 randomized controlled trials, found that minocycline was effective in the treatment of the positive, negative, and general symptoms of schizophrenia, with small to moderate effect sizes.[88] Similarly, a 2023 systematic review and meta-analysis of 10 randomized controlled trials found that minocycline was effective in treating the total, negative, and general symptoms of schizophrenia but not the positive or cognitive symptoms, again with small to moderate effect sizes.
Other conditions
Some early studies suggest that minocycline may be beneficial as an add-on treatment for moderate-to-severe obsessive-compulsive disorder (OCD) when used with a selective serotonin reuptake inhibitor (SSRI).[89][90]
Depression
Minocycline has been studied in the treatment of depression.According to a 2023 systematic review of minocycline for treatment-resistant depression based on four clinical trials, "There is no significant difference with minocycline compared to placebo for depression not responding to first-line antidepressant therapy."[81] Likewise, a 2025 systematic review and meta-analysis of four randomized controlled trials found that minocycline was not significantly more effective than placebo in treating depression.[82] Minocycline might have some benefit in treatment-resistant depression with inflammation however.[83] Yet another meta-analysis, also published in 2023, found that minocycline was effective in the treatment of depression, including treatment-resistant depression, with a small to moderate effect size.[84]
Schizophrenia
Early research has found a tentative benefit from minocycline in schizophrenia,[85] with several trials underway as of 2012.[86] A 2014 meta-analysis found minocycline may reduce negative and total symptom scores and was well tolerated.[87] A 2019 meta-analysis, which included 13 randomized controlled trials, found that minocycline was effective in the treatment of the positive, negative, and general symptoms of schizophrenia, with small to moderate effect sizes.[88] Similarly, a 2023 systematic review and meta-analysis of 10 randomized controlled trials found that minocycline was effective in treating the total, negative, and general symptoms of schizophrenia but not the positive or cognitive symptoms, again with small to moderate effect sizes.
Other conditions
Some early studies suggest that minocycline may be beneficial as an add-on treatment for moderate-to-severe obsessive-compulsive disorder (OCD) when used with a selective serotonin reuptake inhibitor (SSRI).[89][90]
Stroke and neurodegenerative diseases
In ongoing research and trial, minocycline demonstrated efficacy and seems a promising neuroprotective agent in acute stroke patients, especially in AIS subgroup.Further RCTs are needed to evaluate the efficacy and safety of minocycline among ICH patients.[91]
Research is examining the possible neuroprotective and anti-inflammatory effects of minocycline against the progression of a group of neurodegenerative disorders including multiple sclerosis, rheumatoid arthritis, Huntington's disease, and Parkinson's disease.[92][93][94][95] As mentioned above, minocycline harms ALS patients.
A trial found no difference between minocycline and placebo in people with Alzheimer's disease.[96] Minocycline is somewhat neuroprotective in mouse models of Huntington's disease.[97]
Multiple sclerosis
A 2007 study reported the impact of the antibiotic minocycline on clinical and magnetic resonance imaging (MRI) outcomes and serum immune molecules in 40 MS patients over 24 months of open-label minocycline treatment. Despite a moderately high pretreatment relapse rate in the patient group prior to treatment (1.3/year pre-enrollment; 1.2/year during a three-month baseline period), no relapses occurred between months 6 and 24 on minocycline. Also, despite significant MRI disease-activity pretreatment (19/40 scans had gadolinium-enhancing activity during a three-month run-in), the only patient with gadolinium-enhancing lesions on MRI at 12 and 24 months was on half-dose minocycline.Levels of interleukin-12 (IL-12), which at high levels might antagonize the proinflammatory IL-12 receptor, were elevated over 18 months of treatment, as were levels of soluble vascularcell adhesion molecule-1 (VCAM-1).The activity of matrix metalloproteinase-9 was decreased by treatment.Clinical and MRI outcomes in this study were supported by systemic immunological changes and call for further investigation of minocycline in MS.[98][99][100]
Delirium
A 2024 randomized controlled trial found that prophylactic minocycline provided a small but significant decrease in delirium incidence in critically ill patients.[101][102] Unexpectedly, there was also a significant decrease in hospital mortality with minocycline prophylaxis.[101][102] The mortality benefits of minocycline might have simply been due to its bactericidal effects.[103]
Hearing protection
Several preclinical studies (in vitro cell cultures and animal models) suggest that minocycline may have otoprotective benefits. Animal models indicate it could potentially reduce noise-induced and blast-induced hearing loss, possibly by protecting hair cells and mitigating inflammation.[104][105] In vitro and animal studies also show minocycline may help decrease ototoxicity from certain drugs like gentamicin,[106]neomycin,[107] and cisplatin.[108][109]
Other uses
Both minocycline and doxycycline have shown effectiveness in asthma due to immune-suppressing effects.[110] Minocycline and doxycycline have modest effectiveness in treating rheumatoid arthritis.[111] However, the 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis does not include minocycline.[112]
Minocycline also has been used as a "last-ditch" treatment for toxoplasmosis in AIDS patients.[113]
Minocycline has been suggested as a possible treatment for post-COVID-19 syndrome ("long COVID"), but no quality clinical trials exist.[114][115][116] The same is true of minocycline as a potential treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).[115][116][117]
15.Guidelines of care for the management of acne vulgaris J Am Acad Dermatol, May 2024^
16.Doxycycline and minocycline for the management of acne: a review of efficacy and safety with emphasis on clinical implications Journal of Drugs in Dermatology, November 2010^
17.Minocycline Topical Foam: A New Drug for the Treatment of Acne Ann Pharmacother, January 2021^
18.Efficacy of minocycline compared with tetracycline in treatment of acne vulgaris Archives of Dermatology, December 1982^
19.Propionibacterium acnes resistance: a worldwide problem Dermatology, 2003^
20.Antibiotic-resistant acne: lessons from Europe The British Journal of Dermatology, March 2003^
21.Skin and soft tissue infections Primary Care, September 2006^
22.Prophylactic use of antibiotics for prevention of meningococcal infections: systematic review and meta-analysis of randomised trials European Journal of Clinical Microbiology & Infectious Diseases, March 2005^
23.Minocycline--an old drug for a new century: emphasis on methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii International Journal of Antimicrobial Agents, November 2009^
24.A novel use for an old drug: the potential for minocycline as anti-HIV adjuvant therapy The Journal of Infectious Diseases, April 2010^
25.Mycobacterium leprae: Pathogenesis, diagnosis, and treatment options Microbial Pathogenesis, December 2020^
26.U.S. National Library of Medicine (11 December 2009) 'Perioral dermatitis'. Retrieved 7 August 2010.^
42.Medication-associated depersonalization symptoms: report of transient depersonalization symptoms induced by minocycline Southern Medical Journal, January 2004^
43.Drug insight: autoimmune effects of medications-what's new? Nature Clinical Practice. Rheumatology, March 2008^
44.Minocycline in acne vulgaris: benefits and risks American Journal of Clinical Dermatology, 2010^
45.Infectious Diseases of the Female Genital Tract Lippincott Williams & Wilkins, 2001^
46.Ototoxic Drugs Exposed Integrity First Publications, 2010^
48.Minocycline: Possible vestibular side-effects Lancet, September 1974^
49.Vestibular reactions associated with minocycline Antimicrobial Agents and Chemotherapy, October 1975^
50.Medication-induced intracranial hypertension in dermatology American Journal of Clinical Dermatology, 2005^
51.The Ophthalmic Side Effects of Topiramate: A Review Cureus, August 2022^
52.Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome BMJ, January 1996^
53.Autoimmune hepatitis The New England Journal of Medicine, January 2006^
54.Medication-induced intracranial hypertension in dermatology American Journal of Clinical Dermatology, Springer Science and Business Media LLC, 2005^
55.Minocycline-induced hypersensitivity syndrome presenting with meningitis and brain edema: a case report Journal of Medical Case Reports, May 2007^
56."Principles and methods for the assessment of nephrotoxicity associated with exposure to chemicals". Environmental health criteria: 119. World Health Organization (WHO). ISBN 92-4-157119-5. ISSN 0250-863X. 1991^
64.Minocycline, focus on mechanisms of resistance, antibacterial activity, and clinical effectiveness: Back to the future J Glob Antimicrob Resist, September 2020^
65.What is behind the non-antibiotic properties of minocycline? Pharmacol Res, January 2013^
66.Minocycline and Doxycycline: More Than Antibiotics Curr Mol Pharmacol, 2021^
67.Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations Proceedings of the National Academy of Sciences of the United States of America, June 2006^
68.Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia The Journal of Neuroscience, April 2001^
70.A novel mechanism of action of tetracyclines: effects on nitric oxide synthases Proceedings of the National Academy of Sciences of the United States of America, November 1996^
81.Minocycline in depression not responding to first-line therapy: A systematic review and meta-analysis Medicine (Baltimore), November 2023^
82.Efficacy of Minocycline in Depression: A Systematic Review and Meta-analysis Clin Neuropharmacol, 2025^
83.Role of Minocycline as an Adjunct Neuroinflammatory Modulator in Treatment-Resistant Depression: A Systematic Review of Randomized Controlled Trials Prim Care Companion CNS Disord, September 2023^
84.Efficacy and tolerability of minocycline in depressive patients with or without treatment-resistant: a meta-analysis of randomized controlled trials Front Psychiatry, 2023^
85.Minocycline: therapeutic potential in psychiatry CNS Drugs, May 2012^
86.Will Antibiotic Fulfill Its Psychosis-Fighting Promise? Psychiatric News, 17 August 2012^
87.Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta-analysis of randomized controlled trials Human Psychopharmacology, September 2014^
88.Adjunctive minocycline for major mental disorders: A systematic review J Psychopharmacol, October 2019^
89.Treatment-resistant OCD: Pharmacotherapies in adults Comprehensive Psychiatry, January 2023^
90.Minocycline as Treatment for Psychiatric and Neurological Conditions: A Systematic Review and Meta-Analysis International Journal of Molecular Sciences, March 2023^
91.Minocycline for acute stroke treatment: a systematic review and meta-analysis of randomized clinical trials Journal of Neurology, August 2018^
93.Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease Nature Medicine, July 2000^
94.Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia Journal of Immunology, June 2001^
95.Amyotrophic lateral sclerosis: recent advances and future therapies Current Opinion in Neurology, December 2005^
96.Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease: A Randomized Clinical Trial JAMA Neurology, February 2020^
97.Experimental therapeutics in transgenic mouse models of Huntington's disease Nature Reviews. Neuroscience, May 2004^
98.The potential of minocycline for neuroprotection in human neurologic disease Clinical Neuropharmacology, 2004^
99.Multiple neuroprotective mechanisms of minocycline in autoimmune CNS inflammation Neurobiology of Disease, March 2007^
100.Inhibition of autoimmune encephalomyelitis by a tetracycline Annals of Neurology, February 2002^
101.Epidemiological and clinical characteristics of ammonia-producing microorganisms in the lungs of patients with severe pneumonia: a multicentre cohort study J Transl Med, December 2024^
102.Prophylactic Minocycline for Delirium in Critically Ill Patients: A Randomized Controlled Trial Chest, May 2024^
103.Prophylactic Minocycline for Delirium With Unexpected Death Benefits: What Was Treated Unexpectedly? Chest, November 2024^
104.Minocycline attenuates noise-induced hearing loss in rats Neuroscience Letters, February 2017^
105.Effect of minocycline and its nano-formulation on central auditory system in blast-induced hearing loss rat model Journal of Otology, January 2023^
106.Minocycline prevents gentamicin-induced ototoxicity by inhibiting p38 MAP kinase phosphorylation and caspase 3 activation Neuroscience, 2005^
107.Minocycline protection of neomycin induced hearing loss in gerbils BioMed Research International, 2015^
108.Protective Effect of Minocycline Against Cisplatin-induced Ototoxicity Clinical and Experimental Otorhinolaryngology, June 2011^
109.Minocycline attenuates ototoxicity and enhances antitumor activity of cisplatin treatment in vitro Otolaryngology–Head and Neck Surgery, May 2011^
110.Non-antibiotic properties of tetracyclines as anti-allergy and asthma drugs Pharmacological Research, December 2011^
111.The road forward: the scientific basis for tetracycline treatment of arthritic disorders Pharmacological Research, December 2011^
113.Clarithromycin-minocycline combination as salvage therapy for toxoplasmosis in patients infected with human immunodeficiency virus Antimicrobial Agents and Chemotherapy, January 1995^
114.Update of the Potential Treatments for Psychiatric and Neuropsychiatric Symptoms in the Context of the Post-COVID-19 Condition: Still a Lot of Suffering and Many More Things to Learn Trauma Care, 24 March 2022^
115.Could Minocycline Be a "Magic Bullet" for the Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome? Intern Med, August 2021^
116.Oral minocycline therapy as first-line treatment in patients with Myalgic encephalomyelitis and long COVID: A pilot study eNeurologicalSci, March 2025^
117.Oral Minocycline Therapy Improves Symptoms of Myalgic Encephalomyelitis, Especially in the Initial Disease Stage Intern Med, August 2021^
